Results presented here showed negative pressure wound therapy is a safe adjunct for soft tissue sarcoma treated with ...

Iovance Biotherapeutics shares rose after the company shared positive trial results from a treatment designed for soft tissue cancer. The stock gained 26% to $3.65 Tuesday. Shares are still down 32% ...

Objective Response Rate (ORR) in Advanced Sarcomas Significant Market Opportunity with More than 8,000 Patients Diagnosed Annually in the U.S. and Europe SAN CARLOS, Calif., Feb. 24, 2026 (GLOBE ...

An oral combination treatment may prevent the progression of advanced leiomyosarcoma, one of the most common subtypes of soft tissue sarcoma, according to a recent study published in The Lancet ...

LP-284 targets DNA repair defects in cancers, showing promise in preclinical and early clinical trials across multiple cancer types. The FDA's orphan drug designation supports LP-284's development for ...

Third FDA orphan designation for LP-284; Sixth overall for Lantern’s A.I.-driven precision oncology pipeline Orphan designation expands LP-284's potential for an estimated ~96,000 global annual soft ...

Novel biomarkers like GDF15 and OPN show promise in diagnosing and prognosticating uterine sarcoma, potentially enabling early identification and tailored therapy. Blood-based markers such as NLR and ...

Resolute Science Inc.’s RS-5 has been awarded orphan drug designation by the FDA for the treatment of soft tissue sarcomas.

A phase 2a trial shows tigilanol tiglate achieves an 80% response rate in soft tissue sarcoma, offering hope for effective treatment options. Findings from the QB46C-H07 phase 2a clinical trial ...